Aspirin Exacerbated Respiratory Disease Market Global Industry Outlook by Size, Share, Trends and Forecast Till 2028: Apotex Corporation, Pfizer Inc.
The interrelationship between asthma, nasal polyposis and asprin is a classic triad and is known as aspirin exacerbated respiratory disease (AERD). Aspirin exacerbated respiratory disease affects 0.3–0.9% of the population in USA and almost 7% of asthmatic patients. Aspirin exacerbated respiratory disease management is difficult as no single method has proven to have high rates of symptom control. Reactions due to Aspirin Exacerbated Respiratory Disease include shortness of breath, wheezing and worsening of nasal and sinus problems, skin problems such...
View full press release